Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MRKR
Pancreatic data being presented on Saturday, Jul 20 2019 at an AACR meeting during the plenary from 8 to 10 am.
Investor event to follow on Monday July 22 at 1:30 PM.
This is not *really* a binary event for MRKR; all valuations are based on efficacy in hematologic cancers, but if this is positive in a solid tumor (as the fact that AACR granted a plenary would suggest) then there is a ton of upside beyond the potential hematologic indications.
https://www.prnewswire.com/news-releases/marker-therapeutics-to-report-updated-results-from-phase-12-trial-with-multitaa-therapy-in-patients-with-pancreatic-adenocarcinoma-300871612.html
MRKR
Quite a week for this company, all of it presumably in anticipation of the pancreatic cancer results in late July at AACR.
If this is effective in pancreatic without even being optimized for the best antigens, it has the potential to be effective across tumor types, at least those that are immunologically accessible. Could this be the first true pan-tumor treatment?
Hilarious...I was doing a search last night and realized that the world's worst person, aka Martin Shkreli, stopped by here circa 2015. Assuming it was him of course.
And here is an embarrassingly terrible writeup of MRKR from a guy selling a $399/year biotech analysis service on Seeking Alpha who doesn't even have a basic grasp of the biotech industry, molecular biology, or clinical trials. If nothing else it serves as an example of why Seeking Alpha's model is fundamentally flawed.
I posted some criticism of this on the MRKR board but it was immediately deleted--the author is a moderator on the board.
https://seekingalpha.com/article/4271106-marker-therapeutics-cell-therapy-biotech-thinking-outside-box
MRKR to present data from a pancreatic cancer trial on July 20 in a plenary session at AACR, which suggests that the data are quite interesting. Rumor has it that they are very excited to present these data.
I should note that until recently the pancreatic trial was just a side show; the company's focus has been on hematologic cancers. But efficacy in solid tumors would be huge, and any hint of efficacy in pancreatic would be enormous news, not only for the company but also for patients.
https://www.markertherapeutics.com/2019/06/marker-therapeutics-to-report-updated-results-from-phase-1-2-trial-with-multitaa-therapy-in-patients-with-pancreatic-adenocarcinoma/
I was going to say something quite critical about that article but then I realized that someone here wrote it.
Also I just want to note that, at your average meeting, the only people who really look at any posters other than posters that have absolutely critical/groundbreaking clinical data are competitors.
Even they don't really look at them...they usually stop by and take a picture so someone can put it into a competitive analysis
Keep in mind that MRKR management probably had little/nothing to do with writing the abstract, other than maybe getting a courtesy review from the faculty who submitted it, and maybe not even that. Academics like to preserve their "independence" even if it means they are shooting themselves in the foot.
Overall this is a complete non-event--the abstract had no clinical data in it, it was just a design, apparently. So it wasn't rejected on the basis of poor clinical data (nor would ASCO reject an abstract because the data showed a bad result).
The only disappointment is that we do not get to hear about the pancreatic data now.
The technology here is amazing, and the news that ASCO didn't accept a clinical trial design abstract with no clinical data in it is a nonevent.
But they desperately need some medical communications professionals working for them instead of this amateur hour stuff. How do you manage to not get an abstract accepted to ASCO?
AKAO
The bankruptcy filing is a shame.
I don't see how we are ever going to get new antibiotics when the FDA imposes such stringent clinical requirements on these companies that they can't get trials done at any sort of reasonable cost. Their BSI data were, in my opinion, more than sufficient for an indication even if some additional studies would be required.
And of course there is also the huge problem that any new antibiotic gets stuck at the very end of the treatment paradigm so sales of any new antibiotic are minimal. And the problem that the FDA keeps on layering on new Warnings and Precautions for adverse events that rarely occur and this makes new antibiotics appear to be much more dangerous than their older counterparts.
If we want new antibiotics we need a program in which the government provides very generous grants and guarantees to get them developed. In the absence of this it just isn't economically feasible to develop new agents.
I'd never invest in an antibiotic-focused company these days.
CPRX
Note to self: ignore politicians.
I bought CPRX at an average purchase price of $2.30
Then Bernie attacked the company a few months ago and I sold at $2.20. Not a big loss, so okay.
Today it is $5.55
I hate all politicians.